Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094294 | 1.00 | KMT2A (0.38) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16120489 | 0.81 | F2R (0.34) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL22150303 | 0.81 | F2R (0.34) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16094185 | 0.81 | RXRA (0.34) | LMNAMAPTPOLBALDH1A1MITF | |
| SCHEMBL16094186 | 0.81 | RXRA (0.34) | LMNAMAPTPOLBALDH1A1MITF | |
| SCHEMBL16100146 | 0.80 | KMT2A (0.56) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16120475 | 0.80 | HPGDS (0.33) | KMT2ACYP1A2GAAALDH1A1HPGDS | |
| SCHEMBL16094556 | 0.80 | HPGDS (0.33) | KMT2ACYP1A2GAAALDH1A1HPGDS | |
| SCHEMBL16100145 | 0.80 | KMT2A (0.56) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL17709563 | 0.79 | KMT2A (0.34) | KMT2AGAAALDH1A1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | claimed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | claimed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | claimed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | claimed |
| EP-2968331-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | claimed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| EP-2968331-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | DCK, TK1, DTYMK | KMT2A 1361/4885MEN1 2972/4885GABBR2 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.